Women with persistent thyroid hormone imbalance across pregnancy may be at an increased risk of having children with autism, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Maternal thyroid hormones are essential for fetal neurodevelopment. Gestational thyroid imbalance has been associated with atypical neurodevelopment, including increased risk of autism spectrum disorder (ASD). Autism is...
On behalf of the Endocrine Society’s Oncoendocrinology Special Interest Group, Ling Zhu, MBBChir, discusses her recent paper that addressed “the gap in standardized nomenclature, clinical, laboratory and radiological evaluations, and management principles of endocrine- immune-related adverse events (E-irAEs).” She also talks to corresponding author, Afreen Shariff, MD, about the need for nomenclature, the nature of...
Every month is diabetes awareness month at the Endocrine Society. In the United States, November has been set aside for this purpose, allowing healthcare organizations, advocates, and providers to draw attention to this disease that affects millions of people. I’d like to take this opportunity to recap some of the diabetes-related initiatives at the Endocrine...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
On behalf of the Endocrine Society’s Early-Career Special Interest Group (SIG), Milay Luis Lam, MD talks with Early-Career SIG steering group member, Manasi Shah, MD, on bringing science to the transplant bedside and discusses her endocrine journey from her native Mumbai, India, to conducting clinical trials in the U.S. You could say that treating people...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease On Nov. 6, Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine...
A major shift is underway in women’s endocrine health that is changing how the medical community approaches Polycystic Ovary Syndrome (PCOS) and its link to cardiovascular risk. Recent findings published in the European Journal of Endocrinology, titled “Hyperandrogenaemia, Polycystic Ovary Syndrome, and Physical Fitness in Women—a Northern Finland Birth Cohort Study,” stem from a large...
The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare...